Primary biliary cirrhosis in 2014

Current Opinion in Gastroenterology

Volumn 30, Issue 3, 2014, Pages 245-252

  Flores, Avegail ^a   Mayo, Marlyn J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

bezafibrate; budesonide; fenofibrate; obeticholic acid; overlap

Indexed keywords

BEZAFIBRATE; BUDESONIDE; ESTROGEN; FENOFIBRATE; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 12P35; INTERLEUKIN 23; MITOCHONDRIAL PROTEIN; OBETICHOLIC ACID; PYRUVATE DEHYDROGENASE COMPLEX; URSODEOXYCHOLIC ACID; CHOLAGOGUE; FIBRIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BONE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FATIGUE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; ICELAND; IMMUNE RESPONSE; INCIDENCE; JAPAN; LIVER CELL CARCINOMA; NORTH AMERICA; OSTEOPOROSIS; PATHOGENESIS; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; SEX RATIO; SIBLING; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); UNITED KINGDOM; UNITED STATES; GENETIC PREDISPOSITION; LIVER CIRRHOSIS, BILIARY; SEXUAL DEVELOPMENT;

CHOLAGOGUES AND CHOLERETICS; FIBRIC ACIDS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, BILIARY; SEX CHARACTERISTICS; URSODEOXYCHOLIC ACID;

EID: 84898546692     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000058     Document Type: Review

References (77)

1. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012; 56:1181-1188.
2. Metcalf JV, Bhopal RS, Gray J, et al. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England. Int J Epidemiol 1997; 26:830-836.
3. Kim WR, Lindor KD, Locke GR 3rd, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000; 119:1631-1636.
4. Baldursdottir TR, Bergmann OM, Jonasson JG, et al the epidemiology and natural history of primary biliary cirrhosis: a nationwide population-based study. Eur J Gastroenterol Hepatol 2012; 24:824-830.
5. Podda M, Selmi C, Lleo A, et al the limitations and hidden gems of the epidemiology of primary biliary cirrhosis. J Autoimmun 2013; 46:81-87.
6. Selmi C, Invernizzi P, Keeffe EB, et al. Epidemiology and pathogenesis of primary biliary cirrhosis. J Clin Gastroenterol 2004; 38:264-271.
7. Moroni L, Bianchi I, Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmun Rev 2012; 11:A386-392.
8. Medina KL, Garrett KP, Thompson LF, et al. Identification of very early lymphoid precursors in bone marrow and their regulation by estrogen. Nat Immunol 2001; 2:718-724.
9. Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (Baltimore, MD) 2005; 42:1194-1202.
10. Lucey MR, Neuberger JM, Williams R. Primary biliary cirrhosis in men. Gut 1986; 27:1373-1376.
11. Shibata M, Ueno Y, Yoshida N, et al. [Clinical study of male patients with primary biliary cirrhosis (PBC)]. Nihon Shokakibyo Gakkai Zasshi 1990; 87:1846-1850. [in Japanese]
12. Gershwin ME, Mackay IR the causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology (Baltimore, MD) 2008; 47:737-745.
13. Hirschfield GM, Gershwin ME the immunobiology and pathophysiology of primary biliary cirrhosis. Ann Rev Pathol 2013; 8:303-330.
14. Corpechot C, Chretien Y, Chazouilleres O, Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol 2010; 53:162-169.
15. Jones DE, Watt FE, Metcalf JV, et al. Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol 1999; 30:402-407.
16. Selmi C, Mayo MJ, Bach N, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 2004; 127:485-492.
17. Hirschfield GM, Invernizzi P. Progress in the genetics of primary biliary cirrhosis. Semin Liver Dis 2011; 31:147-156.
18. Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009; 360:2544-2555.
19. Nakamura M, Nishida N, Kawashima M, et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet 2012; 91:721-728.
20. Liu X, Invernizzi P, Lu Y, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 2010; 42:658-660.
21. Mells GF, Floyd JA, Morley KI, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 2011; 43:329-332.
22. Angulo PL, Lindor KD. Primary biliary cirrhosis. In: Feldman MF LS, Brandt LJ, editors. Sleisenger and Fordtran's gastrointestinal and liver disease. Philadelphia, PA: Saunders Elsevier Inc.; 2010. pp. 1477-1488.
23. Mayo MJT, Thiele D. Primary biliary cirrhosis. In: Yamada TaeA DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW, editors. Textbook of gastroenterology. Hoboken, NJ: Blackwell Publishing; 2009.
24. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130:715-720.
25. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to urso-deoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepa-tology (Baltimore, MD) 2008; 48:871-877.
26. Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136:1281-1287.
27. Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011; 55:1361-1367.
28. Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105:2186-2194.
29. Azemoto N, Kumagi T, Abe M, et al. Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis. Hepatol Res 2011; 41:310-317.
30. Zhang LN, Shi TY, Shi XH, et al. Early biochemical response to ursodeoxy-cholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology (Baltimore, MD) 2013; 58:264-272.
31. Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxy-cholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999; 117:918-925.
32. Rautiainen H, Karkkainen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology (Baltimore, MD) 2005; 41:747-752.
33. Angulo P, Jorgensen RA, Keach JC, et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology (Baltimore, MD) 2000; 31:318-323.
34. Hempfling W, Grunhage F, Dilger K, et al. Pharmacokinetics and pharma-codynamic action of budesonide in early-and late-stage primary biliary cirrhosis. Hepatology (Baltimore, MD) 2003; 38:196-202.
35. Iwasaki S, Ohira H, Nishiguchi S, et al the efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res 2008; 38:557-564.
36. Levy C, Peter JA, Nelson DR, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Therap 2011; 33:235-242.
37. Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology (Baltimore, MD) 2013; 57:1931-1941.
38. Fiorucci S, Rizzo G, Antonelli E, et al. A farnesoid X receptor-small hetero-dimer partner regulatory cascade modulates tissue metalloproteinase inhibi-tor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Therap 2005; 314: 584-595.
39. Fiorucci S, Antonelli E, Rizzo G, et al the nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004; 127:1497-1512.
40. Fiorucci S, Rizzo G, Antonelli E, et al. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Therap 2005; 315:58-68.
41. Verbeke L, Farre R, Trebicka J, et al. Obeticholic acid, a farnesoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2013. [Epub ahead of print]
42. Mason A, Luketic V, Lindor K, et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of INT-747 to ursodeoxycholic acid. J Hepatol 2010; 52:S1-S2.
43. Michieletti P, Wanless IR, Katz A, et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut 1994; 35:260-265.
44. Taylor SL, Dean PJ, Riely CA. Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am J Surg Pathol 1994; 18:91-99.
45. Lacerda MA, Ludwig J, Dickson ER, et al. Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol 1995; 90:247-249.
46. Moteki S, Leung PS, Coppel RL, et al. Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimito-chondrial autoantibodies. Hepatology (Baltimore, MD) 1996; 24:97-103.
47. Bogdanos DP, Gershwin ME. What is new in primary biliary cirrhosis? Digest Dis (Basel, Switzerland) 2012; 30 (Suppl 1):20-31.
48. Tsuneyama K, Van De Water J, Van Thiel D, et al. Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody-negative primary biliary cirrhosis. Hepatology (Baltimore, MD) 1995; 22:1440-1446.
49. Invernizzi P, Crosignani A, Battezzati PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and-negative primary biliary cirrhosis. Hepatology (Baltimore, MD) 1997; 25: 1090-1095.
50. Sakauchi F, Mori M, Zeniya M, Toda G. Antimitochondrial antibody negative primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid. J Epidemiol 2006; 16:30-34.
51. Gisbert JP, Jones EA, Pajares JM, Moreno-Otero R. Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)? Aliment Pharmacol Therap 2003; 17:17-27.
52. Mayo MJ. Cholestatic liver disease overlap syndromes. Clin Liver Dis 2013; 17:243-253.
53. Yoshioka Y, Taniai M, Hashimoto E, et al. Clinical profile of primary biliary cirrhosis with features of autoimmune hepatitis: importance of corticosteroid therapy. Hepatol Res 2013. [Epub ahead of print]
54. Ozaslan E, Efe C, Heurgue-Berlot A, et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol 2013. [Epub ahead of print]
55. Al-Harthy N, Kumagi T, Coltescu C, Hirschfield GM the specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice. Hepatology (Baltimore, MD) 2010; 52:562-570.
56. Newton JL, Elliott C, Frith J, et al. Functional capacity is significantly impaired in primary biliary cirrhosis and is related to orthostatic symptoms. Eur J Gastroenterol Hepatol 2011; 23:566-572.
57. Mells GF, Pells G, Newton JL, et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology (Baltimore, MD) 2013; 58:273-283.
58. Jones DE, Bhala N, Burt J, et al. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 2006; 55:536-541.
59. Carbone M, Bufton S, Monaco A, et al the effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. J Hepatol 2013; 59:490-494.
60. Rishe E, Azarm A, Bergasa NV. Itch in primary biliary cirrhosis: a patients' perspective. Acta Derm Venereol 2008; 88:34-37.
61. Imamachi N, Park GH, Lee H, et al. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci USA 2009; 106:11330-11335.
62. Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol 2011; 35:89-97.
63. Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis 2012; 16:331-346.
64. Bergasa NV, Thomas DA, Vergalla J, et al. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 1993; 53:1253-1257.
65. Sun YG, Zhao ZQ, Meng XL, et al. Cellular basis of itch sensation. Science (New York, NY) 2009; 325:1531-1534.
66. Carey JB Jr, Williams G. Relief of the pruritus of jaundice with a bile-acid sequestering resin. JAMA 1961; 176:432-435.
67. Ghent CN, Bloomer JR, Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and topruritus. Gastroenterol-ogy 1977; 73:1125-1130.
68. Kremer AE, Martens JJ, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 1018; 139:1008-1018; e1001.
69. Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98:2736-2741.
70. Mayo MJ, Handem I, Saldana S, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology (Baltimore, MD) 2007; 45:666-674.
71. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatol-ogy (Baltimore, MD) 2009; 50:291-308.
72. Guanabens N, Pares A, Ros I, et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 2005; 42:573-577.
73. Guanabens N, Cerda D, Monegal A, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 2010; 138:2348-2356.
74. Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology (Baltimore, MD) 2005; 42:762-771.
75. Guanabens N, Monegal A, Cerda D, et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology 2013; 58:2070-2078.
76. Ormarsdottir S, Mallmin H, Naessen T, et al. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Int Med 2004; 256:63-69.
77. Levy C, Harnois DM, Angulo P, et al. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int 2005; 25:117-121.